Try a new search

Format these results:

Searched for:

in-biosketch:true

person:tanejs01

Total Results:

831


Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): a Randomised Controlled Phase 3 Trial [Comment]

Taneja, Samir S
PMID: 30958755
ISSN: 1527-3792
CID: 4095452

High Response Rates to Neoadjuvant Chemotherapy in High Grade Upper Tract Urothelial Carcinoma

Meng, Xiaosong; Chao, Brian; Vijay, Varun; Silver, Hayley; Margolin, Ezra J; Balar, Arjun; Taneja, Samir S; Shah, Ojas; Bjurlin, Marc A; Anderson, Christopher B; Huang, William C
OBJECTIVES/OBJECTIVE:To evaluate the impact of cisplatin-based neoadjuvant chemotherapy (NAC) in patients who underwent nephroureterectomy for high grade (HG) upper tract urothelial carcinoma (UTUC). METHODS:Retrospective review was conducted of patients with HG UTUC from 2011 to 2017 who underwent nephroureterectomy at two institutions. Patients with eGFR > 50 mL/min/1.73m2 were considered eligible for NAC and were referred for evaluation of NAC prior to nephroureterectomy. Patient demographics, kidney function, clinical and pathologic response rates and outcomes were analyzed. RESULTS:Of 95 patients with HG UTUC meeting inclusion criteria (mean age 72.3 years, mean pre-op eGFR 57.0 mL/min/1.73m2), 61 patients were considered eligible for NAC with eGFR > 50 mL/min/1.73m2, of which 25 (41%) received NAC. Of the patients who received NAC, 80% (20/25) of patients had clinical response on imaging and 80% (20/25) had pathologic response (<pT2N0 disease) on nephroureterectomy. On final pathology, only 20% of the NAC group had ≥pT2 disease compared to 64% of patients who proceeded directly to surgery (p = 0.001). Patients who received NAC had significantly longer progression free survival (p=0.051) and overall survival (p=0.052) compared to patients who proceeded directly to surgery. No patients progressed or were deemed ineligible for surgery due to NAC. CONCLUSIONS:Cisplatin-based NAC demonstrated a high clinical and pathologic response rate in patients with HG UTUC without compromising definitive surgical treatment. Since nephroureterectomy significantly reduces kidney function and eligibility for cisplatin-based chemotherapy after surgery, patients with HG UTUC should be considered for NAC.
PMID: 30930207
ISSN: 1527-9995
CID: 3783792

Re: Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsies

Taneja, Samir S
PMID: 31232650
ISSN: 1527-3792
CID: 3955102

Re: Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends across Risk Groups in the United States, 2010-2015

Taneja, Samir S
PMID: 31232633
ISSN: 1527-3792
CID: 3955082

Re: Value of Increasing Biopsy Cores per Target with Cognitive MRI-Targeted Transrectal US Prostate Biopsy

Taneja, Samir S
PMID: 31232649
ISSN: 1527-3792
CID: 3955092

Re: A 17-Gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility

Taneja, Samir S
PMID: 31063064
ISSN: 1527-3792
CID: 3918932

Re: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Taneja, Samir S
PMID: 31063055
ISSN: 1527-3792
CID: 3918922

Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up

Taneja, Samir S
PMID: 31063072
ISSN: 1527-3792
CID: 3918942

Re: Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer

Taneja, Samir S
PMID: 30747870
ISSN: 1527-3792
CID: 3684802

Re: Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) versus Conventionally Fractionated IMRT for Localized Prostate Cancer

Taneja, Samir S
PMID: 30747871
ISSN: 1527-3792
CID: 3684812